You have accessJournal of UrologyProstate Cancer: Detection and Screening II1 Apr 2015MP60-20 CAN SERUM ADIPOKINES PREDICT THE OUTCOME OF PROSTATE BIOPSIES? AN ASSESSMENT OF THE UTILITY OF SERUM ADIPOKINES IN 2,404 PATIENTS Aza Mohammed, Bimal Bhindi, Michael Jewett, Alexandre Zlotta, Neil Fleshner, and Girish Kulkarni Aza MohammedAza Mohammed More articles by this author , Bimal BhindiBimal Bhindi More articles by this author , Michael JewettMichael Jewett More articles by this author , Alexandre ZlottaAlexandre Zlotta More articles by this author , Neil FleshnerNeil Fleshner More articles by this author , and Girish KulkarniGirish Kulkarni More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.2222AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Obesity and metabolic syndrome have been linked to an increased risk of prostate cancer. Adipokines, cytokines produced by the adipocytes, are found at increased levels in obese patients. Recent studies have linked increased serum adipokines to prostate cancer risk. We assessed the association between serum adipokines and the outcome of prostate biopsies alone and in combination with clinical parameters. Our ultimate goal was to identify whether adipokines could be used as ancillary markers to reduce unnecessary prostate biopsies METHODS Clinical data and serum adipokines were retrieved from three retrospective cohorts representing men at different points in prostate cancer detection: first time biopsy, repeat biopsy after prior negative biopsy and men undergoing repeat biopsy while on active surveillance (AS). 1. Our local GenitoUrinary Biobank was used to identify subjects with no prior biopsies (n=1,061), 2. The placebo arm of the REDUCE trial represented subjects with a prior negative biopsy (n=1,209), 3. Our institutional AS dataset represented patients with low risk prostate cancer on AS (n=134). Adipokines investigated included: Resistin, Tumor Necrosis Factor-α, Interleukin-6 (IL-6), Monocyte Chemoattractant Protein-1 (MCP-1), Hepatocyte Growth Factor, and Nerve Growth Factor. The primary outcome was the absence of prostate cancer on biopsy and the secondary outcome was the diagnosis of low risk prostate cancer fitting the criteria for AS. We used univariate and multivariate logistic regression to assess statistical significance RESULTS In the first cohort (de novo biopsy), IL-6 was found to be a significant predictor for the outcome of prostate biopsies on univariate analysis (OR 1.17. 95%CI=1.05-1.30, p=0.007). This association was not significant after correcting for known clinical predictors. In the second cohort (prior negative biopsy), none of the adipokines assessed were statistically significant predictors for the outcome of prostate biopsies on multivariate analysis. In the third cohort (active surveillance patients), MCP-1 and Resistin were significant predictors for the outcome of subsequent biopsies on multivariate analysis but the point estimates of effect were of questionable clinical significance (OR 1.00 95%CI: 0.99-1.00, p=0.0257 and OR 1.00 95%CI: 1.00-1.00, p=0.0073). CONCLUSIONS Our findings do not support a role for adipokines for predicting the outcome of prostate biopsies at any early stage in diagnosis. More studies are required to validate their role in clinical practice © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e746 Peer Review Report Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Aza Mohammed More articles by this author Bimal Bhindi More articles by this author Michael Jewett More articles by this author Alexandre Zlotta More articles by this author Neil Fleshner More articles by this author Girish Kulkarni More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...